Clinical characteristics and prognostic analysis of 25 patients with mantle cell lymphoma
10.3760/cma.j.issn.1009-9921.2014.08.008
- VernacularTitle:套细胞淋巴瘤25例临床特征及预后分析
- Author:
Jing SHEN
;
Jingshi WANG
;
Na WEI
;
Li FU
;
Dayong HUANG
;
Zhao WANG
- Publication Type:Journal Article
- Keywords:
Lymphoma,mantle-cell;
Rituximab;
Prognosis
- From:
Journal of Leukemia & Lymphoma
2014;23(8):476-479
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the clinical and pathological characteristics,treatment response and clinical follow-up for patients with mantle cell lymphoma (MCL).Methods Clinical data,treatment efficacy and outcomes of 25 cases of MCL enrolled from Beijing Friendship Hospital were retrospectively analyzed.Results Median age of onset was 65 years old.Male to female ratio was 3.4:1,15 cases (60 ％) had bone marrow invasion,Ann Arbor clinical stage Ⅲ were 6 cases (24 ％),stage Ⅳ were 17 cases (68 ％).10 cases (40 ％) of patients had symptoms B.5 cases (20 ％) patients had elevation of lactate dehydrogenase (LDH).17 cases (64 ％) had elevation of β2 microglobulin (β2-MG).11 eases (64.71％) had complete remission (CR) after rituximab combined chemotherapy in 17 patients,2 years overall survival (OS) rate was 69.6 ％,2 years progression-free suvival (PFS) rate was 45.1％,significantly higher than those in traditional chemotherapy group (P ＜ 0.005).Outcomes analyses showed that variants of plasma cells,bone marrow invasion,LDH elevation,Ki-67 level,sMIPI ＞ 5 scores and increased leukocyte number were negative prognostic factors.IPI score,splenomeagly,age,symptoms B and elevation of [β2-MG had no predicative value.Conclusion MCL has higher invasion and poor prognosis.Rituximab combined chemotherapy could significantly improve CR,PFS and OS rates.
